Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzomenib (DSP-5336) in Acute Leukemia and Other Hematologic Malignancies
NCT04988555Phase 2Recruiting
- Sponsor
- Sumitomo Pharma America
- Start
- Feb 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of enzomenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM) and 2 more (14 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Number of patients with adverse events and serious adverse events, Determination of Recommended Phase 2 Dose and 1 more. Started Feb 2022; status: recruiting.
02
Drugs
enzomenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)multiple myeloma (MM)myelodysplastic syndrome (MDS)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT04988555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988555.